Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors

Andrew Horti, Ursula Scheffel, Marigo Stathis, Paige Finley, Hayden T. Ravert, Edythe D. London, Robert F. Dannais

Research output: Contribution to journalArticle

Abstract

Visualization of central nicotinic acetylcholine receptors (nAChRs) with modern PET or SPECT imaging techniques has been hampered by the lack of a radioligand with suitable in vivo binding characteristics (i.e., high target- to-nontarget ratios and kinetics appropriate for the half-life of the tracer and imaging modality used). This paper describes in vive binding, kinetics and pharmacology of a highly potent 18F-labeled analog of epibatidine, (±)-exo-2-(2[18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane ([18F]FPH), in the mouse brain with the view towards application of this tracer for PET imaging of nAChR in human brain. Methods: Fluorine-18-FPH was administered intravenously to mice, and time-activity curves were determined for several regions in the brain and other organs. Saturation and pharmacology of [18F]FPH binding was demonstrated in vivo by preinjecting unlabeled FPH or other drugs with known pharmacological action before [18F]FPH was injected. The effect of the drugs on [18F]FPH accumulation was evaluated. Results: [18F]FPH was rapidly incorporated into the mouse brain; peak activity (2.4% of the injected dose) was measured at 5 min after intravenous administration, followed by washout to 1.1% injected dose (ID) at 60 min. Highest concentrations of 18F occurred at 15 min in areas known to contain high densities of nAChR {e.g., thalamus [9.7% of injected dose per gram tissue (ID/g)] and superior colliculus (8.3% ID/g)}. Accumulation of the 18F tracer in hippocampus, striatum, hypothalamus and cortical areas was intermediate (5.0, 5.6, 4.2 and 5.6% ID/g, respectively) and low in the cerebellum (2.8% ID/g). The distribution of [18F]FPH in the mouse brain matched that of other in vivo nAChR probes such as 3H-labeled epibatidine or norchloroepibatidine, [3H](-)-nicotine and [3H]cytisine and that of nAChR densities determined in postmortem autoradiographic studies in rodents. Preinjection of blocking doses of unlabeled epibatidine, (-)-nicotine, lobeline and cytisine significantly inhibited [18F]FPH binding in thalamus and superior colliculus, but not in cerebellum, whereas drugs that interact with binding sites other than acetylcholine recognition sites of nAChR (e.g., mecamylamine, scopolamine, N-methylspiperone and ketanserin) had no effect on [18F]FPH accumulation in any of the brain regions examined. Conclusion: Fluorine-16-FPH labels nAChR in vivo in the mouse brain. Because of its high uptake into the brain and high ratios of specific-to-nonspecific binding, this radioligand appears to be ideally suited for PET imaging of nAChR in the mammalian brain.

Original languageEnglish (US)
Pages (from-to)1260-1265
Number of pages6
JournalJournal of Nuclear Medicine
Volume38
Issue number8
StatePublished - Aug 20 1997

Keywords

  • Brain imaging
  • Nicotinic acetylcholine receptor
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors'. Together they form a unique fingerprint.

  • Cite this

    Horti, A., Scheffel, U., Stathis, M., Finley, P., Ravert, H. T., London, E. D., & Dannais, R. F. (1997). Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. Journal of Nuclear Medicine, 38(8), 1260-1265.